Welcome to our dedicated page for Century Therapeutics SEC filings (Ticker: IPSC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Century Therapeutics, Inc. (NASDAQ: IPSC) SEC filings page on Stock Titan provides access to the company’s official U.S. regulatory documents, including Forms 10-K, 10-Q, 8-K and other submissions. These filings offer detailed information on Century Therapeutics’ iPSC-derived cell therapy pipeline, financial position and material corporate events.
Century Therapeutics uses its SEC reports to describe its focus on autoimmune diseases, cancer and Type 1 diabetes, its Allo-Evasion™ immune evasion technology, and programs such as CNTY-101, CNTY-308 and CNTY-813. Current reports on Form 8-K have disclosed items like private placement financing arrangements, Nasdaq listing status developments, workforce reductions, board and executive changes, and earnings press releases.
Through periodic filings such as Forms 10-Q and 10-K, investors can review Century Therapeutics’ reported cash, cash equivalents and investments, research and development and general and administrative expenses, collaboration revenue recognition and accumulated deficit. Risk factor and business sections in these reports provide the company’s own discussion of uncertainties related to clinical development, regulatory approvals, collaborations and market conditions.
Stock Titan enhances this information with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand the implications of new documents. Real-time updates from EDGAR ensure that new IPSC filings, including 8-Ks on material events and any Form 4 insider transaction reports, are added as they become available. Use this page to navigate directly to the filings most relevant to your analysis of Century Therapeutics’ business, pipeline and capital structure.
Century Therapeutics, Inc. filed a current report describing updates to its shelf registration and at-the-market equity program. A new Form S-3 shelf registration statement became effective on January 9, 2026, replacing the prior shelf. The company also filed a new prospectus supplement dated March 26, 2026 for its existing at-the-market equity offering program with Cowen and Company, LLC, predecessor to TD Securities (USA) LLC, as sales agent under a July 1, 2022 Sales Agreement. Under this program, the company may issue and sell shares of common stock having an aggregate offering price of up to $150,000,000. It has already sold shares with an aggregate offering price of $18,380,259, leaving up to $131,619,741 of common stock available for future sale under the program.
Century Therapeutics is registering up to $150,000,000 of common stock for sale in an at-the-market offering through TD Cowen pursuant to an existing sales agreement.
The prospectus supplement states 87,519,096 shares outstanding as of December 31, 2025, after giving effect to the January 2026 private placement. Sales will be made from time to time at market prices, TD Cowen will receive a 3.0% commission, and proceeds will be received by the issuer.
Century Therapeutics, Inc. senior vice president of finance and operations Douglas Carr reported an automatic sale of 7,043 shares of common stock at $2.549 per share on March 12, 2026. The filing describes this as an open-market transaction.
According to the footnote, these shares were sold solely to cover tax withholding obligations tied to the vesting of restricted stock units and the sale was not at his discretion. After the transaction, Carr still directly holds 507,261 shares of Century Therapeutics common stock.
Century Therapeutics, Inc. officer Gregory Russotti reported an automatic sale of 10,076 shares of common stock at $2.549 per share. According to the filing, these shares were sold solely to cover tax withholding obligations from vesting restricted stock units and were not sold at his discretion.
After the transaction, Russotti directly holds 515,427 common shares and indirectly holds 92,773 shares through the Gregory Russotti 2021 Family Trust. The activity reflects routine tax-related share withholding rather than a discretionary change in his investment position.
Century Therapeutics, Inc. President and CEO Brent Pfeiffenberger reported a routine tax-related share disposition. The company withheld 55,397 shares of Common Stock at $2.73 per share to cover tax obligations arising from the vesting of restricted stock units. After this withholding, Pfeiffenberger directly holds 3,710,958 shares of Century Therapeutics common stock. This event reflects compensation-related tax settlement rather than an open-market stock sale.
Century Therapeutics, Inc. Chief Scientific Officer Chad Cowan reported a routine tax-related share disposition. On March 11, 2026, 1,431 shares of common stock were withheld by the company at $2.73 per share to satisfy tax obligations tied to vesting restricted stock units, not an open-market sale. After this transaction, Cowan directly holds 1,177,045 shares of common stock. An additional 10,697 shares are held indirectly by the Cowan Investment Nominee Trust, for which he disclaims beneficial ownership except for any pecuniary interest.
IPSC filed a Form 144 notice to sell 10,076 shares of Common Stock tied to a restricted stock vesting event on 03/11/2026.
The filing lists Fidelity Brokerage Services LLC as the broker and shows a prior disposition by Gregory Russotti of 479 shares on 03/09/2026. The excerpt also shows 179,722,750 shares outstanding as of 03/12/2026.
Century Therapeutics reported sharply improved 2025 results while remaining loss-making. Collaboration revenue rose to $109.2M for the year ended December 31, 2025, up from $6.6M in 2024, reflecting a major step-up in partnered activity.
Total operating expenses declined to $126.4M from $144.7M, driven by lower research and development and general and administrative costs, partly offset by $6.8M in asset impairment charges. Net loss narrowed to $9.6M (or $0.14 per share) from $126.6M (or $1.61 per share). As of December 31, 2025, the company held $61.9M in cash and cash equivalents and $55.3M in short-term investments, with total assets of $223.7M and stockholders’ equity of $158.9M. Management highlighted progress on CNTY-813 for type 1 diabetes, targeting an IND as early as the fourth quarter of 2026 and initial clinical data in the second half of 2027.
Century Therapeutics is a biotechnology company developing off-the-shelf allogeneic cell therapies from induced pluripotent stem cells (iPSCs) for type 1 diabetes, autoimmune diseases, and cancer. Its platform combines iPSC reprogramming, CRISPR gene editing, proprietary Allo-Evasion™ immune cloaking, and in-house scalable manufacturing.
The lead program, CNTY-813, is an iPSC-derived beta islet replacement therapy using Allo-Evasion™ 5.0, aiming for durable glycemic control in type 1 diabetes without chronic immunosuppression. CNTY-308 is a CD19-targeted CAR-iT cell candidate for B-cell-mediated diseases, while CNTY-101 is a CD19 CAR-iNK product with six gene edits being evaluated in the CARAMEL Phase 1/2 investigator-sponsored trial in systemic lupus erythematosus, lupus nephritis, idiopathic inflammatory myopathy, and diffuse cutaneous systemic sclerosis.
The company emphasizes deep process and analytical know-how, cryopreservation, and a flexible multi-product facility in New Jersey. It supports its platform with extensive licensing and collaboration agreements, including Fujifilm Cellular Dynamics, iCELL, and Catalent, plus a broad patent estate around iPSCs, differentiation, Allo-Evasion™ technology, and safety switches. As of June 30, 2025, voting stock held by non-affiliates had an aggregate market value of $212,506,473, and as of February 28, 2026 there were 179,722,750 common shares outstanding.
Century Therapeutics, Inc. officer Gregory Russotti reported an automatic sale of 479 shares of common stock on March 9, 2026 at $2.536 per share. According to the footnote, this sale was executed solely to cover tax withholding obligations related to vesting restricted stock units and was not at his discretion.
After the transaction, Russotti directly held 525,503 common shares and also had an indirect holding of 92,773 shares through the Gregory Russotti 2021 Family Trust. The filing therefore reflects a routine tax-related sale while maintaining a substantial ongoing equity position.